$0.7199
0.0034[0.47%]
Last update: 9:29AM Get Real Time Here
Citius Pharma
(NASDAQ:CTXR)Citius Pharma Stock (NASDAQ:CTXR), Analyst Ratings, Price Targets, Predictions
Citius Pharmaceuticals Inc has a consensus price target of $4, established from looking at the 8 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on February 14, 2024, August 10, 2023, and August 1, 2023. With an average price target of $4 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 455.63% upside for Citius Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Maxim Group
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Citius Pharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/14/2024 | CTXR | Buy Now | Citius Pharma | $0.72 | 455.63% | HC Wainwright & Co. | Vernon Bernardino | → $4 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | CTXR | Buy Now | Citius Pharma | $0.72 | 455.63% | HC Wainwright & Co. | Vernon Bernardino | → $4 | Reiterates | Buy → Buy | Get Alert |
| 08/01/2023 | CTXR | Buy Now | Citius Pharma | $0.72 | 455.63% | HC Wainwright & Co. | Vernon Bernardino | $6 → $4 | Maintains | Buy | Get Alert |
| 05/30/2023 | CTXR | Buy Now | Citius Pharma | $0.72 | 733.45% | HC Wainwright & Co. | Vernon Bernardino | → $6 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2023 | CTXR | Buy Now | Citius Pharma | $0.72 | 733.45% | HC Wainwright & Co. | Vernon Bernardino | → $6 | Reiterates | → Buy | Get Alert |
| 03/29/2023 | CTXR | Buy Now | Citius Pharma | $0.72 | 733.45% | HC Wainwright & Co. | Vernon Bernardino | → $6 | Reiterates | → Buy | Get Alert |
| 01/18/2022 | CTXR | Buy Now | Citius Pharma | $0.72 | 733.45% | HC Wainwright & Co. | Vernon Bernardino | $4 → $6 | Maintains | Buy | Get Alert |
| 11/30/2021 | CTXR | Buy Now | Citius Pharmaceuticals | $0.72 | 455.63% | Maxim Group | Michael Okunewitch | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Citius Pharma (CTXR)?
The latest price target for Citius Pharma (NASDAQ: CTXR) was reported by HC Wainwright & Co. on February 14, 2024. The analyst firm set a price target for $4.00 expecting CTXR to rise to within 12 months (a possible 455.63% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Citius Pharma (CTXR)?
The latest analyst rating for Citius Pharma (NASDAQ: CTXR) was provided by HC Wainwright & Co., and Citius Pharma reiterated their buy rating.
When was the last upgrade for Citius Pharma (CTXR)?
There is no last upgrade for Citius Pharma.
When was the last downgrade for Citius Pharma (CTXR)?
There is no last downgrade for Citius Pharma.
When is the next analyst rating going to be posted or updated for Citius Pharma (CTXR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Citius Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Citius Pharma was filed on February 14, 2024 so you should expect the next rating to be made available sometime around February 14, 2025.
Is the Analyst Rating Citius Pharma (CTXR) correct?
While ratings are subjective and will change, the latest Citius Pharma (CTXR) rating was a reiterated with a price target of $0.00 to $4.00. The current price Citius Pharma (CTXR) is trading at is $0.72, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.